^
    3d
    SB101: Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=42, Active, not recruiting, Sonnet BioTherapeutics | Trial completion date: Dec 2024 --> Jun 2026 | Trial primary completion date: Dec 2024 --> Jun 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date • Trial primary completion date • First-in-human
    |
    SON-1010
    3d
    Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=40, Terminated, Sonnet BioTherapeutics | N=165 --> 40 | Trial completion date: May 2025 --> Jan 2026 | Recruiting --> Terminated | Trial primary completion date: Jun 2024 --> Dec 2025; Failed to meet efficacy endpoint criteria, despite lack of safety concerns
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Platinum resistant
    |
    Tecentriq (atezolizumab) • SON-1010
    7d
    Phase Ib/II clinical study to evaluate the safety, tolerability, biodistribution characteristics and preliminary efficacy of Recombinant Human IL-12 Adenovirus Injection (BioTTT001) in the treatment of patients with recurrent/progressive non-small cell lung cancer with meningeal metastasis (ChiCTR2600117576)
    P1/2, N=42, Completed, Henan Cancer Hospital; Henan Cancer Hospital
    New P1/2 trial
    21d
    ADePT: Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma (clinicaltrials.gov)
    P1/2, N=68, Not yet recruiting, Trogenix ltd
    New P1/2 trial
    |
    valacyclovir
    23d
    A Clinical Study of T3011 in Subjects With Advanced Melanoma (clinicaltrials.gov)
    P1/2, N=42, Recruiting, Shanghai Pharmaceuticals Holding Co., Ltd | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    T3011
    23d
    DODEKA: Safety and Early Signs of Efficacy of IL12-L19L19. (clinicaltrials.gov)
    P1, N=80, Recruiting, Philogen S.p.A. | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    dodekin (F8-IL12)
    25d
    MRD: Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Imunon | N=50 --> 30
    Enrollment change
    |
    carboplatin • paclitaxel • IMNN-001
    29d
    ACT: Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, AgonOx, Inc. | Recruiting --> Active, not recruiting | Trial completion date: May 2026 --> Dec 2026 | Trial primary completion date: May 2025 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date • First-in-human
    |
    BRAF (B-raf proto-oncogene) • CD8 (cluster of differentiation 8)
    |
    AGX-148
    1m
    A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, China Medical University, China | N=40 --> 60 | Trial completion date: Dec 2027 --> Dec 2028
    Enrollment change • Trial completion date
    |
    Loqtorzi (toripalimab-tpzi) • Stivarga (regorafenib)
    1m
    A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers (clinicaltrials.gov)
    P1/2, N=55, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: Dec 2025 --> Nov 2026
    Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
    |
    PD-L1 negative
    |
    Jingzhuda (entinostat) • bintrafusp alfa (M7824) • PDS01ADC
    2ms
    A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2062 in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Shanghai Virogin Biotech Co., Ltd.
    New P1 trial
    2ms
    A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma. (clinicaltrials.gov)
    P1/2, N=30, Enrolling by invitation, Beijing Bio-Targeting Therapeutics Technology Co., Ltd | Trial completion date: Aug 2026 --> Jul 2027 | Trial primary completion date: Aug 2026 --> Jul 2027
    Trial completion date • Trial primary completion date